<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Corcept Therapeutics Incorporated — News on 6ix</title>
    <link>https://6ix.com/company/corcept-therapeutics-incorporated</link>
    <description>Latest news and press releases for Corcept Therapeutics Incorporated on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Thu, 30 Apr 2026 20:05:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/corcept-therapeutics-incorporated" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835585878dffbe2df0ea901.webp</url>
      <title>Corcept Therapeutics Incorporated</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated</link>
    </image>
    <item>
      <title>Corcept Phase 2 Study of Dazucorilant Demonstrates Two-Year Overall Survival Benefit in Patients with Amyotrophic Lateral Sclerosis</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-phase-2-study-of-dazucorilant-demonstrates-two-year-overall-survival-benefit-in-patients-with-amyotrophic-lateral-sclerosis</guid>
      <pubDate>Thu, 30 Apr 2026 20:05:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., April 30, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced two-year overall survival data from the Phase 2 DAZALS study of its proprietary, selective cortisol modulator dazucorilant in patients with amyotrophic lateral sclerosis (ALS).</description>
    </item>
    <item>
      <title>Corcept to Present New Data from Pivotal Phase 3 ROSELLA Trial of Lifyorli™ (Relacorilant) in Patients with Platinum-Resistant Ovarian Cancer at ASCO 2026</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-lifyorlitm-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer-at-asco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-to-present-new-data-from-pivotal-phase-3-rosella-trial-of-lifyorlitm-relacorilant-in-patients-with-platinum-resistant-ovarian-cancer-at-asco-2026</guid>
      <pubDate>Tue, 21 Apr 2026 17:09:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., April 21, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, will present new data from its pivotal Phase 3 ROSELLA trial of Lifyorli™ (relacorilant) plus nab-paclitaxel in platinum-resistant ovarian cancer at the 2026 American Society of Clinical Oncology (ASC</description>
    </item>
    <item>
      <title>Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-complete-data-from-pivotal-rosella-trial-in-sgo-late-breaker-with-simultaneous-publication-in-the-lancet-lifyorlitm-relacorilant-plus-nab-paclitaxel-improves-overall-survival-in-patients-with-platinum-resistant-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-complete-data-from-pivotal-rosella-trial-in-sgo-late-breaker-with-simultaneous-publication-in-the-lancet-lifyorlitm-relacorilant-plus-nab-paclitaxel-improves-overall-survival-in-patients-with-platinum-resistant-ovarian-cancer</guid>
      <pubDate>Fri, 10 Apr 2026 04:00:00 GMT</pubDate>
      <description>Data demonstrate a 35 percent reduction in risk of death Lifyorli, in combination with nab-paclitaxel, added to NCCN Guidelines® as a preferred regimen</description>
    </item>
    <item>
      <title>Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-data-from-momentum-trial-at-american-college-of-cardiology-annual-scientific-session</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-data-from-momentum-trial-at-american-college-of-cardiology-annual-scientific-session</guid>
      <pubDate>Sat, 28 Mar 2026 04:00:00 GMT</pubDate>
      <description>Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated</description>
    </item>
    <item>
      <title>Onco360® Has Been Selected as the National Pharmacy Partner for LIFYORLI™ (relacorilant)</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/onco360r-has-been-selected-as-the-national-pharmacy-partner-for-lifyorlitm-relacorilant</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/onco360r-has-been-selected-as-the-national-pharmacy-partner-for-lifyorlitm-relacorilant</guid>
      <pubDate>Thu, 26 Mar 2026 20:30:00 GMT</pubDate>
      <description>LOUISVILLE, Ky., March 26, 2026 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as the national pharmacy partner by Corcept Therapeutics for LIFYORLI™ (relacorilant), which is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.</description>
    </item>
    <item>
      <title>FDA Approves Corcept’s Selective Glucocorticoid Receptor Antagonist Lifyorli™ (relacorilant) Plus Nab-Paclitaxel for Treatment of Patients with Platinum-Resistant Ovarian Cancer</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/fda-approves-corcepts-selective-glucocorticoid-receptor-antagonist-lifyorlitm-relacorilant-plus-nab-paclitaxel-for-treatment-of-patients-with-platinum-resistant-ovarian-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/fda-approves-corcepts-selective-glucocorticoid-receptor-antagonist-lifyorlitm-relacorilant-plus-nab-paclitaxel-for-treatment-of-patients-with-platinum-resistant-ovarian-cancer</guid>
      <pubDate>Wed, 25 Mar 2026 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development</description>
    </item>
    <item>
      <title>Alger Russell Innovation Index Updates for First Quarter 2026</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-first-quarter-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-first-quarter-2026</guid>
      <pubDate>Mon, 16 Mar 2026 20:05:00 GMT</pubDate>
      <description>Fred Alger Management, LLC (&quot;Alger&quot;), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (&quot;Index&quot;). Following the close of trading on Friday, March 20, 2026, the Index will be rebalanced, and the following changes will be effective.</description>
    </item>
    <item>
      <title>Corcept Therapeutics Announces Fourth Quarter and Full-Year 2025 Audited Financial Results, Provides Corporate Update</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announces-fourth-quarter-and-full-year-2025-audited-financial-results-provides-corporate-update</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announces-fourth-quarter-and-full-year-2025-audited-financial-results-provides-corporate-update</guid>
      <pubDate>Tue, 24 Feb 2026 21:05:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., February 24, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the quarter and year ended December 31, 2025.</description>
    </item>
    <item>
      <title>Corcept Provides Update on Patent Dispute with Teva Pharmaceuticals</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-provides-update-on-patent-dispute-with-teva-pharmaceuticals</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-provides-update-on-patent-dispute-with-teva-pharmaceuticals</guid>
      <pubDate>Thu, 19 Feb 2026 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development</description>
    </item>
    <item>
      <title>Corcept Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results, Provide Corporate Update and Host Conference Call</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announce-fourth-quarter-210500963</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announce-fourth-quarter-210500963</guid>
      <pubDate>Tue, 17 Feb 2026 21:05:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif., February 17, 2026--Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report fourth quarter and full-year 2025 financial results and provide a corporate update on February 24, 2026. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).</description>
    </item>
    <item>
      <title>Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3-rosella-trial</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3-rosella-trial</guid>
      <pubDate>Thu, 22 Jan 2026 05:00:00 GMT</pubDate>
      <description>Data demonstrate a 35 percent reduction in the risk of death Both dual primary endpoints (progression-free and overall survival) were met, without the need</description>
    </item>
    <item>
      <title>Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-receives-complete-response-letter-relacorilant-treatment-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-receives-complete-response-letter-relacorilant-treatment-patients</guid>
      <pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development</description>
    </item>
    <item>
      <title>Alger Russell Innovation Index Updates for Fourth Quarter 2025</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-fourth-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-fourth-quarter-2025</guid>
      <pubDate>Mon, 15 Dec 2025 21:18:00 GMT</pubDate>
      <description>Fred Alger Management, LLC (&quot;Alger&quot;), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (&quot;Index&quot;). Following the close of trading on Friday, December 19, 2025, the Index will be rebalanced, and the following changes will be effective.</description>
    </item>
    <item>
      <title>Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announces-third-quarter-financial-results-oncology-development</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announces-third-quarter-financial-results-oncology-development</guid>
      <pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
      <description>Revenue of $207.6 million, compared to $182.5 million in third quarter 2024 Modified 2025 revenue guidance of $800 – $850 million Net income of $19.7</description>
    </item>
    <item>
      <title>Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announce-third-quarter-financial-results-provide-corporate</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-therapeutics-announce-third-quarter-financial-results-provide-corporate</guid>
      <pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and</description>
    </item>
    <item>
      <title>Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-esmo-2025-late-breaker-relacorilant-demonstrates-benefit-patients</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-presents-esmo-2025-late-breaker-relacorilant-demonstrates-benefit-patients</guid>
      <pubDate>Sun, 19 Oct 2025 04:00:00 GMT</pubDate>
      <description>New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with</description>
    </item>
    <item>
      <title>Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-submits-marketing-authorization-application-european-medicines-agency</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-submits-marketing-authorization-application-european-medicines-agency</guid>
      <pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development</description>
    </item>
    <item>
      <title>Curant Rare Announces Pharmacy Partnership with Corcept Therapeutics</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/curant-rare-announces-pharmacy-partnership-with-corcept-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/curant-rare-announces-pharmacy-partnership-with-corcept-therapeutics</guid>
      <pubDate>Wed, 01 Oct 2025 13:00:00 GMT</pubDate>
      <description>ATLANTA, October 01, 2025--Curant Health is proud to announce that Curant Rare has been selected by Corcept Therapeutics as a specialty pharmacy to provide personalized care, coordinated access to therapy, and comprehensive support to help patients and caregivers navigate the complexities of treatment.</description>
    </item>
    <item>
      <title>Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-present-new-late-breaking-data-pivotal-rosella-trial-relacorilant-platinum</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/corcept-present-new-late-breaking-data-pivotal-rosella-trial-relacorilant-platinum</guid>
      <pubDate>Mon, 22 Sep 2025 04:00:00 GMT</pubDate>
      <description>REDWOOD CITY, Calif.--(BUSINESS WIRE)-- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development</description>
    </item>
    <item>
      <title>Alger Russell Innovation Index Updates for Third Quarter 2025</title>
      <link>https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-third-quarter-2025</link>
      <guid isPermaLink="true">https://6ix.com/company/corcept-therapeutics-incorporated/news/alger-russell-innovation-index-updates-for-third-quarter-2025</guid>
      <pubDate>Mon, 15 Sep 2025 20:25:00 GMT</pubDate>
      <description>Fred Alger Management, LLC (&quot;Alger&quot;), a privately held growth equity investment manager, today announced the quarterly rebalancing of the Alger Russell Innovation Index (&quot;Index&quot;). Following the close of trading on Friday, September 19, 2025, the Index will be rebalanced, and the following changes will be effective.</description>
    </item>
  </channel>
</rss>